Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H16O8 |
Molecular Weight | 408.3576 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C(C1=C(O)C2=C(OC1=O)C=CC=C2)C3=C(O)C4=C(OC3=O)C=CC=C4
InChI
InChIKey=JCLHQFUTFHUXNN-UHFFFAOYSA-N
InChI=1S/C22H16O8/c1-2-28-20(25)15(16-18(23)11-7-3-5-9-13(11)29-21(16)26)17-19(24)12-8-4-6-10-14(12)30-22(17)27/h3-10,15,23-24H,2H2,1H3
Molecular Formula | C22H16O8 |
Molecular Weight | 408.3576 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14885082
Curator's Comment: Tromexan was synthesized by von Reinis and Kubik in 1948.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q9BQB6 Gene ID: 79001.0 Gene Symbol: VKORC1 Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Tromexan Approved UseThromboses, thrombophlebitis, pulmonary embolisms, thromboembolic episodes at a myocardial infarction, heart failure. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8351679/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: TRISILOXANE |
ETHYL BISCOUMACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
31 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8351679/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHYL BISCOUMACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7874379/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHYL BISCOUMACETATE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.03 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7874379/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
7-HYDROXY ETHYL BISCOUMACETATE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://go.drugbank.com/drugs/DB08794 |
yes |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13057879
The initial dosage was 900 to 1,800 mg (usually 1,200 or 1,500 mg). The subsequent dosage was judged by daily prothrombin time determinations. Daily maintenance dosage ranged from 300 to 900 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7203295
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:03:06 GMT 2023
by
admin
on
Sat Dec 16 18:03:06 GMT 2023
|
Record UNII |
08KL644731
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
B01AA08
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
||
|
WHO-VATC |
QB01AA08
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
||
|
NCI_THESAURUS |
C263
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
||
|
EPA PESTICIDE CODE |
11901
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
325
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
1091
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
208-940-5
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
m5095
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | Merck Index | ||
|
C75157
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
D005017
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
SUB07285MIG
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
100000082601
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
Ethyl biscoumacetate
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
548-00-5
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL81697
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
54685524
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
36366
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
DB08794
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
DTXSID3057771
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY | |||
|
08KL644731
Created by
admin on Sat Dec 16 18:03:06 GMT 2023 , Edited by admin on Sat Dec 16 18:03:06 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
Unit: percent of administered drug; No anticoagulant activity
IN-VIVO
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |